SCHEMBL12015186

SCHEMBL12015186

COC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)C(O)[C@H]1OC

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HINT1 P49773 6/20 0.63
NT5E P21589 1/20 0.61
GSK3A P49840 2/20 0.57
RPS6KA3 P51812 2/20 0.57
MAPK14 Q16539 2/20 0.57
TGM2 P21980 1/20 0.56
PNP P00491 1/20 0.55
ADORA3 P0DMS8 1/20 0.54
HPGD P15428 1/20 0.54
IMPDH2 P12268 1/20 0.53
IMPDH1 P20839 1/20 0.53
FUT5 Q11128 1/20 0.53
STING1 Q86WV6 1/20 0.52
KRAS P01116 2/20 0.51
TAS1R3 Q7RTX0 1/20 0.51
TAS1R1 Q7RTX1 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24247659 1.00 HINT1 (0.63) HINT1NT5EGSK3ARPS6KA3MAPK14
SCHEMBL12087512 1.00 HINT1 (0.63) HINT1NT5EGSK3ARPS6KA3MAPK14
SCHEMBL12590129 1.00 HINT1 (0.63) HINT1NT5EGSK3ARPS6KA3MAPK14
SCHEMBL4369228 1.00 HINT1 (0.63) HINT1NT5EGSK3ARPS6KA3MAPK14
SCHEMBL4371108 0.92 HINT1 (0.63) HINT1NT5EGSK3ARPS6KA3MAPK14
SCHEMBL17972356 0.91 HINT1 (0.61) HINT1NT5EGSK3ARPS6KA3MAPK14
SCHEMBL17976623 0.91 HINT1 (0.61) HINT1NT5EGSK3ARPS6KA3MAPK14
SCHEMBL23679991 0.91 HINT1 (0.61) HINT1NT5EGSK3ARPS6KA3MAPK14
SCHEMBL22883381 0.91 HINT1 (0.61) HINT1NT5EGSK3ARPS6KA3MAPK14
SCHEMBL16359926 0.91 HINT1 (0.61) HINT1NT5EGSK3ARPS6KA3MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120220649-A1 MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220649-A1 MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE POLM, POLN, PNKP HINT1 2414/4885NT5E 104/4885GSK3A 4490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.